Answers are grounded in this paper and cite their sources.
EU legislation offers an exclusive marketing period as an incentive for companies to develop drugs for rare diseases. But pricing for orphan drugs hinders access and may warrant a competition law investigation, say Jonathan C P Roos, Hanna I Hyry, and Timothy M Cox
No takes yet. Share an insight, caveat, or question.
Roos et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: